Literature DB >> 7192948

Anoxic cerebral potassium accumulation reduced by phenytoin: mechanism of cerebral protection?

A A Artru, J D Michenfelder.   

Abstract

Results from a previous study suggested that the cerebral protective effect of phenytoin (PNT) might be linked to its ability to reduce cerebrospinal fluid potassium (K+) accumulation during anoxia. In the present study two PNT doses (50 and 150 mg/kg) were examined to determine the ability of PNT to reduce cerebrospinal fluid K+ in cisterna magna samples after 10 and 20 minutes of circulatory arrest. Also examined were two other protective treatments (pentobarbital, 33 mg/kg, and hypothermia to 35 C) which, in the hypoxic (F1O2 = 0.05) mouse, provide cerebral protection equivalent to PNT, 50 mg/kg. Both PNT doses significantly reduced cerebrospinal fluid K+ accumulation and tended to do so in a dose-related manner, similar to the dose-related cerebral protective effect of PNT. PNT, 50 mg/kg reduced K+ accumulation more effectively than either pentobarbital or hypothermia, whose protective effects are likely explained by a different mechanism (i.e., reduced cerebral metabolic rate). These data support the hypothesis that PNT-induced cerebral protection may be linked to its effect on cerebral K+ accumulation.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7192948

Source DB:  PubMed          Journal:  Anesth Analg        ISSN: 0003-2999            Impact factor:   5.108


  3 in total

Review 1.  Brain protection: physiological and pharmacological considerations. Part II: The pharmacology of brain protection.

Authors:  R Hall; J Murdoch
Journal:  Can J Anaesth       Date:  1990-10       Impact factor: 5.063

2.  The anaesthetist and the head-injured patient.

Authors:  A W Gelb; P H Manninen; B J Mezon; R J Lee; Q J Durward
Journal:  Can Anaesth Soc J       Date:  1984-01

3.  Neuroprotective properties of lifarizine compared with those of other agents in a mouse model of focal cerebral ischaemia.

Authors:  C M Brown; C Calder; C Linton; C Small; B A Kenny; M Spedding; L Patmore
Journal:  Br J Pharmacol       Date:  1995-08       Impact factor: 8.739

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.